her2 car-t cell
Cell therapyexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 3, 2021 (NCT04903080)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2Immunity, passive
ERBB2 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06027983 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2023 | National University of Singapore |
| NCT06101082 | Phase 1 | Oct 25, 2023 | China Medical University, Government of China |
| NCT04903080 | Phase 1 | Sep 3, 2021 | Baylor University, Pediatric Brain Tumor Consortium |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baylor University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| China Medical University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Government of China | Government | 1 | 0 | 1 | 2023 |
| National University of Singapore | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Pediatric Brain Tumor Consortium | Academic/Hospital | 1 | 1 | 1 | 2021 |
5 organizations
Page 1 / 1